Rasi Returns: Ousted EMA Executive Director Gets Job Back
Executive Summary
Agenda likely to include patient engagement, trial transparency and adaptive pathways for the well-respected leader who lost post due to procedural challenges.
You may also be interested in...
EMA Leadership Goes To Pott After Rasi Retroactively Unhired
Andreas Pott, who helped steer agency through Mediator scandal, becomes acting director again as irregularities in 2011’s recruitment process force departure of Guido Rasi – who himself might still get top job again once hiring process reboots.
MEPs Pass Clinical Trials Laws But Implementation Will Be Troublesome
Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.